Anthem Biosciences has 3.04% of equity traded in blocks

Anthem Biosciences Limited reported that 3.04% of its equity was traded in block deals, indicating significant institutional or large-scale investor activity. Block trades often reflect strategic positioning by major stakeholders and can signal confidence or caution in the company's future performance. This development comes amid recent market movements, including a 1.6% decline in the stock price, which has brought the share closer to key support levels following a mild correction.

The company, a leading player in the life sciences and biotechnology sector, has been expanding its manufacturing and research capabilities, including increasing its custom synthesis and fermentation capacities over the past several years. Anthem Biosciences also recently completed a major initial public offering in July 2025, raising significant capital through an offer for sale.

The stock currently trades at Rs. 777.1 as of May 24, 2026, with a 52-week range between Rs. 579.15 and Rs. 873.5. Investors are closely monitoring both trading patterns and upcoming quarterly results, particularly in light of recent insider trading disclosures reported before the Q2 earnings release.